140 related articles for article (PubMed ID: 34828291)
21. A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.
Giordano CR; Mueller KL; Terlecky LJ; Krentz KA; Bollig-Fischer A; Terlecky SR; Boerner JL
Exp Cell Res; 2012 Oct; 318(16):2014-21. PubMed ID: 22687878
[TBL] [Abstract][Full Text] [Related]
22. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
23. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Yang Z; Hu X; Zhang S; Zhang W; Tam KY
Eur J Pharmacol; 2017 Nov; 815():80-87. PubMed ID: 28870456
[TBL] [Abstract][Full Text] [Related]
25. Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFR
Orlandi P; Di Desidero T; Salvia G; Muscatello B; Francia G; Bocci G
Biochem Pharmacol; 2018 Jun; 152():327-337. PubMed ID: 29660315
[TBL] [Abstract][Full Text] [Related]
26. Tyrosine dephosphorylation enhances the therapeutic target activity of epidermal growth factor receptor (EGFR) by disrupting its interaction with estrogen receptor (ER).
Ma S; Yin N; Qi X; Pfister SL; Zhang MJ; Ma R; Chen G
Oncotarget; 2015 May; 6(15):13320-33. PubMed ID: 26079946
[TBL] [Abstract][Full Text] [Related]
27. miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway.
Han J; Zhao F; Zhang J; Zhu H; Ma H; Li X; Peng L; Sun J; Chen Z
Int J Oncol; 2016 May; 48(5):1855-67. PubMed ID: 26936292
[TBL] [Abstract][Full Text] [Related]
28. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Collins DM; Crown J; O'Donovan N; Devery A; O'Sullivan F; O'Driscoll L; Clynes M; O'Connor R
Invest New Drugs; 2010 Aug; 28(4):433-44. PubMed ID: 19499189
[TBL] [Abstract][Full Text] [Related]
30. Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Choi YJ; Park GM; Rho JK; Kim SY; So GS; Kim HR; Choi CM; Lee JC
PLoS One; 2013; 8(12):e81393. PubMed ID: 24339922
[TBL] [Abstract][Full Text] [Related]
31. Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
Zhang D; Tari AM; Akar U; Arun BK; LaFortune TA; Nieves-Alicea R; Hortobagyi GN; Ueno NT
Mol Cancer Ther; 2010 Nov; 9(11):3090-9. PubMed ID: 21045138
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration.
Papanastasiou AD; Sirinian C; Kalofonos HP
Breast Cancer Res; 2012 Jul; 14(4):R112. PubMed ID: 22824341
[TBL] [Abstract][Full Text] [Related]
33. K
Glaser F; Hundehege P; Bulk E; Todesca LM; Schimmelpfennig S; Nass E; Budde T; Meuth SG; Schwab A
Sci Rep; 2021 Sep; 11(1):18330. PubMed ID: 34526525
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
35. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
36. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
38. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
39. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
40. NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers.
Wang X; Yin H; Zhang H; Hu J; Lu H; Li C; Cao M; Yan S; Cai L
Cell Death Dis; 2018 Apr; 9(4):418. PubMed ID: 29549343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
